Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
St. Antonius Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03718559CT.gov Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Coronary Artery Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Edoxaban (this asset) | St. Antonius Hospital | Approved | BB · 68 |
| Aspirin | Rajaie Cardiovascular Medical and Research Center | P4 | BBB |
| Ezetimibe | Canadian Collaborative Research Network | P4 | BBB |
| Simvastatin | University of Washington | P4 | BBB |
| Rivaroxaban | Sheffield Teaching Hospitals NHS Foundation Trust | P4 | BBB |
| Ranolazine | OBS Pakistan | P4 | BBB |
| Pitavastatin | Yokohama City University Medical Center | P4 | BBB |
| Clopidogrel | Beijing Tiantan Hospital | P4 | BB |
| Fluvastatin | Yokohama City University Medical Center | P4 | BB |
+40 more in the Coronary Artery Disorder cohort
Other indications for Edoxaban
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Atrial Fibrillation | — | P4 | A · 83 |
| Intracerebral Hemorrhage | — | P4 | BBB · 78 |
| Atrial Flutter | — | P4 | BBB · 75 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Edoxaban in Coronary Artery Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/edoxaban-coronary-artery-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →